| Dr Gerardo Ortiz, MD | |
|
400 W 16th St, Pueblo, CO 81003-2745 | |
| (719) 584-4595 | |
| (719) 584-4861 |
| Full Name | Dr Gerardo Ortiz |
|---|---|
| Gender | Male |
| Speciality | Emergency Medicine |
| Location | 400 W 16th St, Pueblo, Colorado |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1437361573 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | 46280 (Colorado) | Primary |
| Entity Name | Third Coast Emergency Physicians Southwest Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1497793475 PECOS PAC ID: 6800794447 Enrollment ID: O20031222000126 |
News Archive
Orexigen commends CEO as well as the author of the report, Alex Brill , and the Robert Wood Johnson Foundation (RWJF) who funded the report, for this new research illustrating the importance of long-term budget impact analyses on preventive health policies, specifically those aimed at obesity.
Medtronic, Inc. today announced the U.S. Food and Drug Administration (FDA) has classified the company's previous action related to the Octopus® Nuvo Tissue Stabilizer as a Class I recall. FDA classifies a recall as Class I when the agency believes that there is a reasonable probability that use of the recalled product will cause serious adverse health consequences or death. On Sept. 14, 2010, Medtronic proactively and voluntarily recalled the device from the market due to the potential that a component of the device could fracture during use.
Biomagnetics Diagnostics Corp., a developer of revolutionary diagnostic systems and technology for HIV, hepatitis, tuberculosis and malaria detection, and other innovative technologies, today announced the signing of a Letter of Intent (LOI) with Lanzhou New Sunshine Plastics Industry LTD. This expected acquisition is the fourth planned acquisition targeted at a share price of US $1.50 for Biomagnetics Diagnostics' common shares.
Myrexis, Inc., a biotechnology company focused on discovering, developing, and commercializing novel treatments for cancer, today announced key findings from preclinical studies of the Company's novel cancer metabolism inhibitor (CMI), MPC-9528, at the Cancer and Metabolism Pathways to the Future Symposium in Edinburgh, Scotland.
A new study finds that iPhone software applications designed to help people quit smoking fall short of the mark because they do not meet accepted standards.
› Verified 2 days ago
| Entity Name | Travis County Emergency Physicians Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1962440933 PECOS PAC ID: 0840289468 Enrollment ID: O20040510000492 |
News Archive
Orexigen commends CEO as well as the author of the report, Alex Brill , and the Robert Wood Johnson Foundation (RWJF) who funded the report, for this new research illustrating the importance of long-term budget impact analyses on preventive health policies, specifically those aimed at obesity.
Medtronic, Inc. today announced the U.S. Food and Drug Administration (FDA) has classified the company's previous action related to the Octopus® Nuvo Tissue Stabilizer as a Class I recall. FDA classifies a recall as Class I when the agency believes that there is a reasonable probability that use of the recalled product will cause serious adverse health consequences or death. On Sept. 14, 2010, Medtronic proactively and voluntarily recalled the device from the market due to the potential that a component of the device could fracture during use.
Biomagnetics Diagnostics Corp., a developer of revolutionary diagnostic systems and technology for HIV, hepatitis, tuberculosis and malaria detection, and other innovative technologies, today announced the signing of a Letter of Intent (LOI) with Lanzhou New Sunshine Plastics Industry LTD. This expected acquisition is the fourth planned acquisition targeted at a share price of US $1.50 for Biomagnetics Diagnostics' common shares.
Myrexis, Inc., a biotechnology company focused on discovering, developing, and commercializing novel treatments for cancer, today announced key findings from preclinical studies of the Company's novel cancer metabolism inhibitor (CMI), MPC-9528, at the Cancer and Metabolism Pathways to the Future Symposium in Edinburgh, Scotland.
A new study finds that iPhone software applications designed to help people quit smoking fall short of the mark because they do not meet accepted standards.
› Verified 2 days ago
| Entity Name | Leading Edge Emergency Physicians, Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1003165259 PECOS PAC ID: 2466601588 Enrollment ID: O20121005000189 |
News Archive
Orexigen commends CEO as well as the author of the report, Alex Brill , and the Robert Wood Johnson Foundation (RWJF) who funded the report, for this new research illustrating the importance of long-term budget impact analyses on preventive health policies, specifically those aimed at obesity.
Medtronic, Inc. today announced the U.S. Food and Drug Administration (FDA) has classified the company's previous action related to the Octopus® Nuvo Tissue Stabilizer as a Class I recall. FDA classifies a recall as Class I when the agency believes that there is a reasonable probability that use of the recalled product will cause serious adverse health consequences or death. On Sept. 14, 2010, Medtronic proactively and voluntarily recalled the device from the market due to the potential that a component of the device could fracture during use.
Biomagnetics Diagnostics Corp., a developer of revolutionary diagnostic systems and technology for HIV, hepatitis, tuberculosis and malaria detection, and other innovative technologies, today announced the signing of a Letter of Intent (LOI) with Lanzhou New Sunshine Plastics Industry LTD. This expected acquisition is the fourth planned acquisition targeted at a share price of US $1.50 for Biomagnetics Diagnostics' common shares.
Myrexis, Inc., a biotechnology company focused on discovering, developing, and commercializing novel treatments for cancer, today announced key findings from preclinical studies of the Company's novel cancer metabolism inhibitor (CMI), MPC-9528, at the Cancer and Metabolism Pathways to the Future Symposium in Edinburgh, Scotland.
A new study finds that iPhone software applications designed to help people quit smoking fall short of the mark because they do not meet accepted standards.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Gerardo Ortiz, MD 400 W 16th St, Pueblo, CO 81003-2745 Ph: (719) 584-4595 | Dr Gerardo Ortiz, MD 400 W 16th St, Pueblo, CO 81003-2745 Ph: (719) 584-4595 |
News Archive
Orexigen commends CEO as well as the author of the report, Alex Brill , and the Robert Wood Johnson Foundation (RWJF) who funded the report, for this new research illustrating the importance of long-term budget impact analyses on preventive health policies, specifically those aimed at obesity.
Medtronic, Inc. today announced the U.S. Food and Drug Administration (FDA) has classified the company's previous action related to the Octopus® Nuvo Tissue Stabilizer as a Class I recall. FDA classifies a recall as Class I when the agency believes that there is a reasonable probability that use of the recalled product will cause serious adverse health consequences or death. On Sept. 14, 2010, Medtronic proactively and voluntarily recalled the device from the market due to the potential that a component of the device could fracture during use.
Biomagnetics Diagnostics Corp., a developer of revolutionary diagnostic systems and technology for HIV, hepatitis, tuberculosis and malaria detection, and other innovative technologies, today announced the signing of a Letter of Intent (LOI) with Lanzhou New Sunshine Plastics Industry LTD. This expected acquisition is the fourth planned acquisition targeted at a share price of US $1.50 for Biomagnetics Diagnostics' common shares.
Myrexis, Inc., a biotechnology company focused on discovering, developing, and commercializing novel treatments for cancer, today announced key findings from preclinical studies of the Company's novel cancer metabolism inhibitor (CMI), MPC-9528, at the Cancer and Metabolism Pathways to the Future Symposium in Edinburgh, Scotland.
A new study finds that iPhone software applications designed to help people quit smoking fall short of the mark because they do not meet accepted standards.
› Verified 2 days ago
Mary Russo, DO Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 400 W 16th St, Pueblo, CO 81003 Phone: 719-584-4306 Fax: 719-595-7886 | |
Teresa Kay Braden, D.O. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 311 W 14th St, Pueblo, CO 81003 Phone: 719-595-7585 Fax: 719-595-7589 | |
Kyle Delbar, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 400 W 16th St, Pueblo, CO 81003 Phone: 719-584-4595 | |
Elizabeth Brittany Skewes, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 400 W 16th St, Pueblo, CO 81003 Phone: 719-584-4306 Fax: 719-595-7886 | |
Michael Todd Duzan, DO Emergency Medicine Medicare: Medicare Enrolled Practice Location: 401 W Northern Ave, Pueblo, CO 81004 Phone: 719-553-0400 Fax: 719-553-0401 | |
Dr. Scott W Calcagno, D.O. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 400 W 16th St, Pueblo, CO 81003 Phone: 719-584-4306 Fax: 719-595-7886 | |
Dr. David James Joyce, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 400 W 16th St, Pueblo, CO 81003 Phone: 719-584-4306 Fax: 719-584-4861 |